REGULATORY
PAFSC’s 2nd Committee to Discuss GSK’s CLL Treatment Arzerra on January 31
The Pharmaceutical Affairs and Food Sanitation Council’s Second Committee on Drugs, an advisory organ of the Minister of Health, Labor and Welfare will discuss two products/indications, including GlaxoSmithKline’s Arzerra for I.V. Infusion (ofatumumab) on January 31. Arzerra, a humanized monoclonal…
To read the full story
REGULATORY
- Japan Approves AbbVie’s Aquipta, Novo’s IcoSema, Pfizer’s Tukysa, and More
February 20, 2026
- Takaichi Urges Public-Private Investment Push in Drug Discovery
February 20, 2026
- Two iPSC-Derived Products Now in Line for Conditional Approval
February 20, 2026
- PM Takaichi Keeps Cabinet Intact after Lower House Vote
February 18, 2026
- LDP Returnees Set Sights on Social Security, Drug Policy as Special Diet Opens
February 18, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…





